Shreyas Gangadhara, MD
Neurology · Jackson, MSNPI 1992092548
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,733 of the $20,357 with a category attached, or 77.3%. AstraZeneca accounts for 85.6% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2022 at $13,584 and has fallen 99.4% since, to $82 in 2025.
Across 168 payments — averaging $121.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$17K
- UCB, Inc.$336
- Acadia Pharmaceuticals Inc$246
- CSL Behring$222
- Novartis$214
- Biohaven Pharmaceutical Holding Company Ltd.$190
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$15,73377%
- Travel & lodging$1,1015%
- Food & beverage$3,52317%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 28 | $17,430 |
| UCB, Inc. | 13 | $336 |
| Acadia Pharmaceuticals Inc | 14 | $246 |
| CSL Behring | 4 | $222 |
| Novartis | 10 | $214 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $190 |
| Livanova USA, Inc. | 2 | $189 |
| Biohaven Pharmaceuticals, Inc. | 11 | $178 |
| Sanofi | 9 | $150 |
| SK Life Science, Inc. | 6 | $149 |
| AbbVie(2 entities) | 7 | $111 |
| Amgen | 5 | $103 |
| Eisai Inc. | 7 | $98 |
| Neurocrine Biosciences, Inc. | 6 | $86 |
| Ceribell, Inc. | 1 | $75 |
| Teva Pharmaceuticals USA, Inc. | 5 | $74 |
| Avanir Pharmaceuticals, Inc. | 4 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Acorda Therapeutics, Inc | 3 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Pfizer | 2 | $35 |
| Lundbeck LLC | 1 | $34 |
| Biogen | 2 | $34 |
| EMD Serono, Inc. | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 2 | $26 |
| Greenwich Biosciences, Inc. | 1 | $20 |
| Amylyx Pharmaceuticals, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Grifols USA, LLC | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRILINTA$17,146
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$151
- ANDEXXA$113
How this compares
$20,357 in reported general payments places this provider in the 80th percentile of 111 neurology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 17 | $22,982 |
| VimpatLacosamide | 12 | $13,812 |
| Repatha SureclickEvolocumab | 13 | $7,181 |
| Lacosamide | 30 | $1,569 |
| Levetiracetam | 42 | $1,262 |
| Gabapentin | 31 | $686 |
| Atorvastatin Calcium | 86 | $613 |
| Pregabalin | 27 | $330 |
| Donepezil Hcl | 40 | $219 |
| Ezetimibe | 15 | $209 |
| Baclofen | 11 | $193 |
| Amitriptyline Hcl | 32 | $168 |
| ClopidogrelClopidogrel Bisulfate | 28 | $147 |
| Rosuvastatin Calcium | 15 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $35 | $22,98217 claims |
| UCB, Inc.Vimpat | $336 | $13,81212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 neurology providers in Mississippi.
Other neurology in Jackson
- Ruth FredericksJackson$943K
- Wendell HelvestonJackson$883K
- Rajesh SharmaJackson$152K
- Patrick WeldonJackson$85K
- Riichi OtaJackson$53K
- Mitchell MyersJackson$43K
- Tiffany ScarffJackson$29K
- Derek LetortJackson$25K
- Juebin HuangJackson$20K
- David McHenryJackson$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.